The reasons this study is being conducted are: • To see if human immunodeficiency virus (HIV) antiretroviral medicines that you are taking continue to work well in transgender women and other individuals identifying as female or transfeminine but with male sex assigned at birth (referred to as transgender women throughout this form) when taken with feminizing hormone therapy (FHT), also known in this study as estradiol; and • To see if estradiol levels in blood vary between boosted and un-boosted HIV medicines when transgender women are taking different doses of FHT.

To demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection. To estimate efficacy of Bexsero in prevention of overall gonococcal infection and by anatomical site (urogenital, anorectal or pharyngeal). To assess safety of Bexsero.

To assess the influence of HIV-related and CVD-related variables in the existing WIHS study, including viral load, immune dysfunction, inflammation, metabolic disorders, HIV medications, gut microbiota, and metabolomics, on CVD risk as measured by cIMT.

The purpose of this study is to tell if a disinfectant wipe with a blue dye additive increases the thoroughness of cleaning and disinfection and reduces contamination.

The goal of this study is to develop new ways of figuring out which children with acute respiratory illnesses (like cough, cold, or flu) would benefit from antibiotic treatment. To do this, we will evaluate different combinations of vital signs, symptoms, results from tests for infections that cause respiratory illness, and measurement of the body's immune response to see which ones best predict the presence of infection that requires antibiotic treatment.

To find out if certain study treatments (study interventions) can help treat exercise intolerance and post-exertional malaise that started or got worse after a COVID-19 infection and have lasted for at least 3 months

The goal of the ABACUS-HIV Study is to learn about things that make it easier or more difficult for people with HIV to take their cholesterol medication consistently. WHAT WILL YOU BE ASKED TO DO? Be interviewed for 60-75 minutes in clinic or by phone; All your responses will be confidential; Participants will be compensated $50. WHO CAN JOIN? People living with HIV; At least 18 years old; Prescribed a cholesterol medication called a statin; Can speak English; Have agreed to be in the HIV clinic database at UNC. Patients interested in participating should contact the study team at (919) 843-2532.

This is a Phase 2 Crossover Study of On Demand PrEP Formulations Comparing Rectal and Oral TFV-Based PrEP

To learn more about the experimental drug, ISL/LEN. This includes: Comparing ISL/LEN weekly to B/F/TAF daily and determining which of these study treatments works better for treating HIV infection. Determining how ISL/LEN and B/F/TAF affects the HIV infection in the body. Testing and learning about the safety of ISL/LEN, how well ISL/LEN is tolerated, and how long it stays in the body using physical exam, blood and urine tests, and any symptoms or problems it may create in the study.

The purpose of this expanded access IND (compassionate use) program is to provide tecovirimat for treatment or prevention of non-variola orthopoxvirus infections (e.g., vaccinia, monkeypox, cowpox or other human virus infection identified as an orthopoxvirus) and secondary treatment of complications from replication-competent vaccinia vaccine in adults and children.